Friends! In this video, I'm going to do an analysis on Paypal stock, BMY stock and TGT stock
3 extracted signals · 3 resolved · 0 still active
The Patient InvestorIndependent analyst profile- Source published
- 20 Sept 2025, 19:29 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
AI-generated source summary
The video provides a fundamental analysis of three stocks: PayPal (PYPL), Bristol-Myers Squibb (BMY), and Target (TGT).For PYPL, the analysis notes a 61% decline over five years, indicating a long base formation, and growing active accounts. Despite revenue growth deceleration, it's accelerating. With $7B in free cash flow and significant share buybacks, the analyst infers a target price of $100. The analysis will be invalidated at $60.BMY trades at seven times earnings with a sustainable dividend yield. Despite impending patent expirations, the video highlights BMY’s strategy of acquiring new drugs to maintain free cash flow. It is assigned a target of $60 and fail price of $40.Target's comp sales have been negative and depend greatly on discretionary expenditures, resulting in a negative outlook. The analysis will be invalidated at a price of $95, with an inferred target of $70.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
3 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
The Patient Investor
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.